0735 ET - Surgery Partners' reduced 2024 free cash flow outlook and a hiccup in 3Q same-facility revenue growth roused investor concerns that are looking excessive at this point, Benchmark analyst Bill Sutherland says in a research note. The company's stock has fallen nearly 40% since its 3Q report last month, but the free cash flow guidance was primarily impacted by Surgery Partners opportunistically deploying about $340 million for M&A, the analyst says. And entering 2025, the company's same-facility revenue growth algorithm, combined with higher M&A, should drive double-digit revenue growth, Sutherland says, maintaining a buy rating on the stock. (dean.seal@wsj.com)
(END) Dow Jones Newswires
December 26, 2024 07:35 ET (12:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.